Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Clearmind Medicine Inc.
< Previous
1
2
3
4
Next >
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
August 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
July 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
June 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
May 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
May 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
May 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
May 12, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
May 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
May 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
April 27, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
April 20, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Closes US$3.5 Million Public Offering
April 06, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
April 04, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
March 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
March 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
January 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.